Here we investigated in a group of treatment naive RRMS patients whether the CSF levels of GFAP and sTREM-2 are associated with central inflammation, quantified by measuring the intrathecal levels of specific proinflammatory and anti-inflammatory cytokines at the time of diagnosis. This evidence concerns the gene GFAP and relapsing-remitting multiple sclerosis.